A Practical Approach to the Management of Residual Cardiovascular Risk: United Arab Emirates Expert Consensus Panel on the Evidence for Icosapent Ethyl and Omega-3 Fatty Acids.

Autor: Sabbour H; Warren Alpert School of Medicine, Brown University, RI USA, Mediclinic Hospital, Abu Dhabi, United Arab Emirates. hanisabbour1@icloud.com., Bhatt DL; Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, NY, USA. DLBhattMD@post.Harvard.edu., Elhenawi Y; Heart And Vascular Institute, Cleveland Clinic, Abu Dhabi, United Arab Emirates., Aljaberi A; Endocrine Division, Department of Medicine, Tawam Hospital, Abu Dhabi, United Arab Emirates., Bennani L; Medical Affairs, Biologix, Dubai, United Arab Emirates., Fiad T; Centre Abu Dhabi, Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates., Hasan K; Packer Hospital Guthrie, Sayre, Pennsylvania, USA., Hashmani S; Heart And Vascular Institute, Cleveland Clinic, Abu Dhabi, United Arab Emirates., Hijazi RA; Department of Endocrinology, Diabetes and Metabolism, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates., Khan Z; Department of Cardiology, Sheikh Shakhbout Medical City, Abu Dhabi, United Arab Emirates., Shantouf R; Heart And Vascular Institute, Cleveland Clinic, Abu Dhabi, United Arab Emirates.
Jazyk: angličtina
Zdroj: Cardiovascular drugs and therapy [Cardiovasc Drugs Ther] 2024 Feb 16. Date of Electronic Publication: 2024 Feb 16.
DOI: 10.1007/s10557-023-07519-z
Abstrakt: Purpose: Patients with hyperlipidemia treated with statins remain at a residual cardiovascular (CV) risk. Omega-3 polyunsaturated fatty acids hold the potential to mitigate the residual CV risk in statin-treated patients, with persistently elevated triglyceride (TG) levels.
Method: We reviewed the current evidence on the use of icosapent ethyl (IPE), an omega-3 fatty acid yielding a pure form of eicosapentaenoic acid.
Results: REDUCE-IT reported a significant 25% reduction in CV events, including the need for coronary revascularization, the risk of fatal/nonfatal myocardial infarction, stroke, hospitalization for unstable angina, and CV death in patients on IPE, unseen with other omega-3 fatty acids treatments. IPE was effective in all patients regardless of baseline CV risk enhancers (TG levels, type-2 diabetes status, weight status, prior revascularization, or renal function). Adverse events (atrial fibrillation/flutter) related to IPE have occurred mostly in patients with prior atrial fibrillation. Yet, the net clinical benefit largely exceeded potential risks. The combination with other omega-3 polyunsaturated fatty acids, in particular DHA, eliminated the effect of EPA alone, as reported in the STRENGTH and OMEMI trials. Adding IPE to statin treatment seems to be cost-effective, especially in the context of secondary prevention of CVD, decreasing CV event frequency and subsequently the use of healthcare resources.
Conclusion: Importantly, IPE has been endorsed by 20 international medical societies as a statin add-on treatment in patients with dyslipidemia and high CV risk. Robust medical evidence supports IPE as a pillar in the management of dyslipidemia.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: